HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High-dose tamoxifen reverses drug resistance to cisplatin and etoposide in a patient with advanced large cell carcinoma of lung.

Abstract
A 64-year-old man was diagnosed as having large cell carcinoma of lung and suffered from recurrent tumors after repeated surgical resection and local irradiation. Systemic chemotherapy with chronic oral etoposide, and then 5 courses of intravenous cisplatin and etoposide (PE) resulted in disease progression with multiple new lung nodules and a severe superior vena cava syndrome. Empirical treatment with a PET regimen, which incorporated high-dose tamoxifen (TAM) 150 mg/m2/day into original PE regimen, was tried. Nearly total tumor necrosis was achieved after 5 courses of PET with remission duration of 4.5 months. The excellent response by simple addition of TAM into a previously inactive PE regimen advocates further investigation.
AuthorsK H Yeh, A L Cheng
JournalAnticancer research (Anticancer Res) 1997 Mar-Apr Vol. 17 Issue 2B Pg. 1341-3 ISSN: 0250-7005 [Print] Greece
PMID9137495 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Tamoxifen
  • Etoposide
  • Cisplatin
Topics
  • Antineoplastic Agents, Hormonal (pharmacology)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carcinoma, Large Cell (drug therapy)
  • Cisplatin (administration & dosage)
  • Drug Resistance
  • Etoposide (administration & dosage)
  • Humans
  • Lung Neoplasms (drug therapy)
  • Male
  • Middle Aged
  • Tamoxifen (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: